Genentech, Inc.

The University of Texas System

Mark Merchant

Stephanie Royer Joo

Jennifer Lee Schutzman

Marie Anne Evangelista

Ting-Kun Mark Lin

Sandhya Vinayak Mandlekar

Stuart G Lutzker

Deepak Sampath

Marcia Belvin

Klaus Hoeflich

Marina Konopleva

Neekesh Vijay Dharia

Zhen Shi

John Moffat

Chunyan Song

Lina Han

Marina Yurievna Konopleva

Provided herein are combination therapies comprising a KRasinhibitor (e.g. Compound 1 or a pharmaceutically acceptable salt thereof) and a VEGF antagonist (e.g., bevacizumab) and methods of using such combination therapies.

Methods and compositions comprising a KRasinhibitor and a VEGF inhibitor for treating solid tumors

Provided herein are combination therapies comprising GDC-6036 and inavolisib and methods of using the same to treat cancer.

Treatment of cancer using combination therapies comprising GDC-6036 and GDC-0077

Provided herein are combination therapies (compositions) and methods and uses thereof for the treatment lung cancer, where the combination therapies comprise Compound 1 or a pharmaceutically acceptable salt thereof as described herein and a PD-L1 binding antagonist (e.g., atezolizumab).

Methods and compositions comprising a KRASG12C inhibitor and a PD-L1 binding antagonist for treating lung cancer

The present invention is directed to a combination therapy involving a selective Bcl-2 inhibitor and a MEK inhibitor for the treatment of a patient in need of such a therapy. The patient in need of the combination therapy is suffering from cancer, such as acute myeloid leukemia.

Combination of Bcl-2 inhibitor and MEK inhibitor for the treatment of cancer

The invention provides combinations comprising a MEK inhibitor (such as GDC-0973 or GDC-0623), or a pharmaceutically acceptable salt thereof and an ERK inhibitor (such as GDC-0994). The combinations are particularly useful for treating hyperproliferative disorders, such as cancer.

Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases

The invention provides a combination of a) a compound of Formula Ia: [insert Formula Ia], or a pharmaceutically acceptable salt thereof, and b) vemurafenib or a pharmaceutically acceptable salt thereof for the prophylactic or therapeutic treatment of a hyperproliferative disorder, such as cancer. 

Combinations of AKT inhibitor compounds and vemurafenib, and methods of use

Growing community of inventors

South San Francisco, CA, United States of America

Mark Merchant